Cargando…

Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling

BACKGROUND: To better understand the etiology and pathomechanisms of Alzheimer’s disease, several transgenic animal models that overexpress human tau or human amyloid-beta (Aβ) have been developed. In the present study, we generated a novel transgenic rat model by cross-breeding amyloid precursor pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Filip, Thomas, Mairinger, Severin, Neddens, Joerg, Sauberer, Michael, Flunkert, Stefanie, Stanek, Johann, Wanek, Thomas, Okamura, Nobuyuki, Langer, Oliver, Hutter-Paier, Birgit, Kuntner, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522096/
https://www.ncbi.nlm.nih.gov/pubmed/34656177
http://dx.doi.org/10.1186/s13195-021-00916-2
_version_ 1784585026014281728
author Filip, Thomas
Mairinger, Severin
Neddens, Joerg
Sauberer, Michael
Flunkert, Stefanie
Stanek, Johann
Wanek, Thomas
Okamura, Nobuyuki
Langer, Oliver
Hutter-Paier, Birgit
Kuntner, Claudia
author_facet Filip, Thomas
Mairinger, Severin
Neddens, Joerg
Sauberer, Michael
Flunkert, Stefanie
Stanek, Johann
Wanek, Thomas
Okamura, Nobuyuki
Langer, Oliver
Hutter-Paier, Birgit
Kuntner, Claudia
author_sort Filip, Thomas
collection PubMed
description BACKGROUND: To better understand the etiology and pathomechanisms of Alzheimer’s disease, several transgenic animal models that overexpress human tau or human amyloid-beta (Aβ) have been developed. In the present study, we generated a novel transgenic rat model by cross-breeding amyloid precursor protein (APP) rats with tau rats. We characterized this model by performing positron emission tomography scans combined with immunofluorescent labeling and cerebrospinal fluid analyses. METHODS: APP/Tau rats were generated by cross-breeding male McGill-R-Thy1-APP transgenic rats with female hTau-40/P301L transgenic rats. APP/Tau double transgenic rats and non-transgenic (ntg) littermates aged 7, 13, and 21 months were subjected to dynamic [(11)C] PiB scan and dynamic [(18)F]THK-5317 scans. For regional brain analysis, a template was generated from anatomical MR images of selected animals, which was co-registered with the PET images. Regional analysis was performed by application of the simplified reference tissue model ([(11)C]PiB data), whereas [(18)F]THK-5317 data were analyzed using a 2-tissue compartment model and Logan graphical analysis. In addition, immunofluorescent labeling (tau, amyloid) and cerebrospinal fluid analyses were performed. RESULTS: [(11)C]PiB binding potential (BP(ND)) and [(18)F]THK-5317 volume of distribution (V(T)) showed an increase with age in several brain regions in the APP/Tau group but not in the ntg control group. Immunohistochemical analysis of brain slices of PET-scanned animals revealed a positive correlation between Aβ labeling and [(11)C]PiB regional BP(ND). Tau staining yielded a trend towards higher levels in the cortex and hippocampus of APP/Tau rats compared with ntg littermates, but without reaching statistical significance. No correlation was found between tau immunofluorescence labeling results and the respective [(18)F]THK-5317 V(T) values. CONCLUSIONS: We thoroughly characterized a novel APP/Tau rat model using combined PET imaging and immunofluorescence analysis. We observed an age-related increase in [(11)C]PiB and [(18)F]THK-5317 binding in several brain regions in the APP/Tau group but not in the ntg group. Although we were able to reveal a positive correlation between amyloid labeling and [(11)C]PiB regional brain uptake, we observed relatively low human tau and amyloid fibril expression levels and a somewhat unstable brain pathology which questions the utility of this animal model for further studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00916-2.
format Online
Article
Text
id pubmed-8522096
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85220962021-10-21 Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling Filip, Thomas Mairinger, Severin Neddens, Joerg Sauberer, Michael Flunkert, Stefanie Stanek, Johann Wanek, Thomas Okamura, Nobuyuki Langer, Oliver Hutter-Paier, Birgit Kuntner, Claudia Alzheimers Res Ther Research BACKGROUND: To better understand the etiology and pathomechanisms of Alzheimer’s disease, several transgenic animal models that overexpress human tau or human amyloid-beta (Aβ) have been developed. In the present study, we generated a novel transgenic rat model by cross-breeding amyloid precursor protein (APP) rats with tau rats. We characterized this model by performing positron emission tomography scans combined with immunofluorescent labeling and cerebrospinal fluid analyses. METHODS: APP/Tau rats were generated by cross-breeding male McGill-R-Thy1-APP transgenic rats with female hTau-40/P301L transgenic rats. APP/Tau double transgenic rats and non-transgenic (ntg) littermates aged 7, 13, and 21 months were subjected to dynamic [(11)C] PiB scan and dynamic [(18)F]THK-5317 scans. For regional brain analysis, a template was generated from anatomical MR images of selected animals, which was co-registered with the PET images. Regional analysis was performed by application of the simplified reference tissue model ([(11)C]PiB data), whereas [(18)F]THK-5317 data were analyzed using a 2-tissue compartment model and Logan graphical analysis. In addition, immunofluorescent labeling (tau, amyloid) and cerebrospinal fluid analyses were performed. RESULTS: [(11)C]PiB binding potential (BP(ND)) and [(18)F]THK-5317 volume of distribution (V(T)) showed an increase with age in several brain regions in the APP/Tau group but not in the ntg control group. Immunohistochemical analysis of brain slices of PET-scanned animals revealed a positive correlation between Aβ labeling and [(11)C]PiB regional BP(ND). Tau staining yielded a trend towards higher levels in the cortex and hippocampus of APP/Tau rats compared with ntg littermates, but without reaching statistical significance. No correlation was found between tau immunofluorescence labeling results and the respective [(18)F]THK-5317 V(T) values. CONCLUSIONS: We thoroughly characterized a novel APP/Tau rat model using combined PET imaging and immunofluorescence analysis. We observed an age-related increase in [(11)C]PiB and [(18)F]THK-5317 binding in several brain regions in the APP/Tau group but not in the ntg group. Although we were able to reveal a positive correlation between amyloid labeling and [(11)C]PiB regional brain uptake, we observed relatively low human tau and amyloid fibril expression levels and a somewhat unstable brain pathology which questions the utility of this animal model for further studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00916-2. BioMed Central 2021-10-16 /pmc/articles/PMC8522096/ /pubmed/34656177 http://dx.doi.org/10.1186/s13195-021-00916-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Filip, Thomas
Mairinger, Severin
Neddens, Joerg
Sauberer, Michael
Flunkert, Stefanie
Stanek, Johann
Wanek, Thomas
Okamura, Nobuyuki
Langer, Oliver
Hutter-Paier, Birgit
Kuntner, Claudia
Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
title Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
title_full Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
title_fullStr Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
title_full_unstemmed Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
title_short Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
title_sort characterization of an app/tau rat model of alzheimer’s disease by positron emission tomography and immunofluorescent labeling
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522096/
https://www.ncbi.nlm.nih.gov/pubmed/34656177
http://dx.doi.org/10.1186/s13195-021-00916-2
work_keys_str_mv AT filipthomas characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT mairingerseverin characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT neddensjoerg characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT sauberermichael characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT flunkertstefanie characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT stanekjohann characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT wanekthomas characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT okamuranobuyuki characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT langeroliver characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT hutterpaierbirgit characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling
AT kuntnerclaudia characterizationofanapptauratmodelofalzheimersdiseasebypositronemissiontomographyandimmunofluorescentlabeling